A phase I trial of PS-341 [bortezomib] in combination with topotecan in advanced solid tumor malignancies

Trial Profile

A phase I trial of PS-341 [bortezomib] in combination with topotecan in advanced solid tumor malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Topotecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Planned end date changed from 1 Oct 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top